SPS
ALNY icon

Susquehanna Portfolio Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,005
Closed -$1.66M – 849
2026
Q1 		$1.66M Hold
5,005
– – 0.02% 540
2025
Q4 		$1.99M Hold
5,005
– – 0.03% 501
2025
Q3 		$2.28M Hold
5,005
– – 0.04% 487
2025
Q2 		$1.63M Buy
+5,005
New +$1.38M 0.04% 410

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna Portfolio Strategies's ALNY Position: Q2 2026 in Review

Susquehanna Portfolio Strategies sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 5,005 shares — an estimated $1.66M sold.

Susquehanna Portfolio Strategies first reported a position in ALNY in Q2 2025 and held it in 4 quarters. The position peaked at $2.28M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Susquehanna Portfolio Strategies reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 5,005 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.66M.
  • Susquehanna Portfolio Strategies first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Susquehanna Portfolio Strategies's Alnylam Pharmaceuticals position peaked at $2.28M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.